Biotech Values

[RockRat]

"A less important point is that it's also true that amphastar got FDA approval without violating the 466 patent . . ."

This is not established. Momenta chose not to argue that patent because the limited discovery did not give them enough information to argue it conclusively. With the full discovery that will attend the trial, the '466 patent might very well be in play.

Regards, RockRat